Clinical Trial Finder

Inclusion Criteria:

Participants must have a documented diagnosis of multiple myeloma (MM)

• - Participants with measurable disease defined as at least one of the following: - Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or.

• - Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or.

• - Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).

• - Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.

• - A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods.

• - Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.

• - Capable of giving signed informed consent.

Exclusion Criteria:

• - Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course.

• - Participants with prior anti-CD38 treatment if: a) administered <9 months before first isatuximab administration or randomization as applicable or, b) Intolerant to the anti-CD38 previously received.

• - Prior treatment with carfilzomib.

• - Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents.

• - Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis.

• - Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

The duration of the study for a participant will include a period for screening of up to 28 days. A cycle duration is 28 days. Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue treatment, or any other reason, as well as the study treatment is commercially available and reimbursed in the participant's country, or is available from another source, whichever is first. The overall study duration will be of approximately 45 months.

Arms

Experimental: Cohort 1: manual administration

Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter.

Experimental: Part 1 Cohort 2: manual administration

Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter.

Experimental: Part 2 Randomized Cohort: OBDS to manual

Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration.

Experimental: Part 2 Randomized Cohort: Manual to OBDS

Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration.

Interventions

Drug: - Isatuximab

Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous

Drug: - Carfilzomib

Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous

Drug: - Dexamethasone

Pharmaceutical form: Tablet; Route of administration: Oral

Drug: - Dexamethasone IV

Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous